linjc16/ctgov huggingface dataset:
Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders

Study Overview
=================
Brief Summary
-----------------
The main objective is to constitute a precise and exhaustive collection of clinical data (somatic and neurobehavioral data) of individuals affected by various frequent monogenic forms of neurodevelopmental disorders to better characterize the clinical phenotype of these disorders. A better knowledge of these manifestations is necessary to improve the management of individuals with these disorders. The secondary objectives of this research are to inform practitioners, patients and their families about the clinical characteristics of these disorders to better understand their diversity and, finally, to improve their screening and diagnosis. Thus, our study aims at establishing clinical scores, linking genotypes and phenotypes and producing documents for professionals (such as the PNDS (National Diagnostic and Care Protocols))

Official Title
-----------------
Somatic and Neurobehavioral Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders

Conditions
-----------------
Neurodevelopmental Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Minor patient whose age is ≥ 4 years and ≤18 years Major patient with intellectual disability Patient treated in a participating center for TND linked to a mutation in one of the genes frequently mutated in this pathology, such as the DYRK1A, KMT2A or other genes; Patient having previously been seen in genetic consultation Parent (or legal guardian) not having expressed, after information, his opposition to the reuse of his data for the purposes of this research. Exclusion criteria: - Parent (or legal guardian) who expressed his opposition to participating in the study.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of clinical profiles associated to different monogenic form of NDD |  | Files analysed retrospectively from January 01, 2015 to March 31, 2020 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neurodevelopmental disorders, Rare disease, Genetic Diseases, Monogenic syndromes, Intellectual Disability, Autism spectrum disorder, Neurobehavioral Manifestations
Effects of Isolated Rooms on the Prevalence of Hospital Acquired Pneumonia in a Respiratory ICU

Study Overview
=================
Brief Summary
-----------------
This study will carry out in the ICU. Objectives of the study are to determine the frequency of HAP and the effect of isolated rooms on the frequency of pneumonia in the ICU.

Detailed Description
-----------------
In the present study, it was aimed to determine the incidence, causative agents, antimicrobial resistance, and risk factors for lower respiratory tract infections in patients followed in the ICU for the last 4 years. The effect of reconfiguration from a ward-type ICU consisting one large room to an ICU with isolated rooms with two beds on the incidence of HAP was also determined.

Official Title
-----------------
Epidemiologic Study of Hospital Acquired Pneumonia in a Respiratory ICU

Conditions
-----------------
Pneumonia, Intensive Care Unit

Intervention / Treatment
-----------------
* Other: ward-type ICU


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients, admitted to the ICU Exclusion Criteria: trauma, surgery or burned patients patients under 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hospital acquired pneumonia<br> | |
| isolated rooms<br> | Other: ward-type ICU<br>* frequency of hospital acquired pneumonia in the ICU<br>* Other names: frequency of hospital acquired pneumonia in the ICU;|
| ward-type ICU<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pneumonia, ICU, isolation room, clinical epidemiology, infection control
Analysis of Hospitalization Data From ZOC

Study Overview
=================
Brief Summary
-----------------
The real-world electronic health records (EHR) were derived from the hospitalization of Zhongshan Ophthalmic Center (ZOC) of Sun Yat-sen University from 1998-2020 to investigate the ophthalmology diagnosis and treatment activities.

Official Title
-----------------
Analysis of Hospitalization Data in Zhongshan Ophthalmology Center

Conditions
-----------------
Ophthalmology, Hospitalization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have retrospective inpatient records of ZOC from 1998 to 2020 Exclusion Criteria: Demographic data missing Diagnosis data missing
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| inpatients of ZOC<br>Patients have retrospective hopitalization record of ZOC from 1998 to 2020. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of primary diagnosis | calculate the prevalence of the primary diagnosis of inpatient visits | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of secondary diagnosis | calculate the prevalence of the secondary diagnosis of inpatient visits | baseline | 
| Demographics | Demographics of inpatient visits | baseline | 
| costs of inpatient visits | costs of inpatient visits | baseline |
Ketamine and Closed-Loop Anesthesia System

Study Overview
=================
Brief Summary
-----------------
The objective is to evaluate the sparing effect of ketamine on the dose of propofol.

Official Title
-----------------
Influence of Ketamine on a Closed-Loop Anesthesia System

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Drug: Ketamine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with an American Society of Anesthesiology score 1, 2 or 3 scheduled for a surgical procedure lasting more than 2 hours under general anesthesia Exclusion Criteria: pregnancy chronic pain simultaneous general and loco-regional anesthesia contra-indication to to nonsteroidal anti-inflammatory drug contra-indication to Ketamine contra-indication to propofol, to remifentanil, to morphine history of central nervous system disease patients receiving a psychotropic treatment patients with a pace-maker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketamine<br>Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia) | Drug: Ketamine<br> <br> |
| Experimental: Placebo<br>patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group) | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| administered dose of propofol during maintenance of anesthesia |  | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bispectral index measurement | bispectral index modification due to ketamine infusion before induction of anesthesia | 1 day | 
| administered dose of propofol during induction of anesthesia |  | day 1 | 
| administered doses of remifentanil during induction and maintenance of anesthesia |  | day 1 | 
| delay (measured as minutes) between the end of propofol and remifentanil administration and the recovery from anesthesia |  | day 1 | 
| hemodynamic abnormalities requiring treatment |  | day 1 | 
| % of time with a bispectral index between 40 and 60 |  | day 1 | 
| postoperative morphine requirement |  | day 1 | 
| incidence of postoperative nausea and vomiting |  | day 1 | 
| White and Song score |  | day 1 | 
| % of patients with an explicit memorisation of the intraoperative period |  | second postoperative day |
Epidural Steroid Following Discectomy for Herniated Disc Reduces Morbidity

Study Overview
=================
Brief Summary
-----------------
Focus of this study is evaluation of the outcome, neurologic impairment and safety of epidural steroide following lumbar discectomy for herniated disc disease.

Detailed Description
-----------------
Methylprednisolone might enhance recovery after discectomy for herniated disc disease without apparent side effect. Convalescence after discectomy for herniated disc disease is dependent on pain and the inflammatory response. In arthroscopic and abdominal surgery steroids reduce the inflammatory response and enhance recovery. 200 patients with herniated disc disease are randomly allocated to receive epidural methylprednisolone 40 mg or none.

Official Title
-----------------
Epidural Steroid Following Discectomy for Herniated Lumbar Disc Reduces Neurological Impairment and Enhances Recovery. A Randomized Study With Two-year Follow-up

Conditions
-----------------
Disc Disease

Intervention / Treatment
-----------------
* Drug: Methylprednisolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with primary lumbar herniated disc disease who had received and performed standardized conservative treatment program with intensive exercises Patients more than 18 years old Exclusion Criteria: Patients with central or lateral spinal stenosis due to spondylosis or disc degeneration who needed bilateral decompression, laminectomy or fusion Patients with cauda equina syndrome who needed acute operative treatment Lack of informed consent and inability to read and understand Danish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 66 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Epidural steroid<br>1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root | Drug: Methylprednisolone<br>* Epidural methylprednisolone 40 mg or none<br>|
| Experimental: None epidural steroid<br> | Drug: Methylprednisolone<br>* Epidural methylprednisolone 40 mg or none<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms and signs of neurologic impairment and rate of operation during a 2-year follow-up. |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital stay, back and leg pain and reflex deficit. |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
discectomy, methylprednisolone, randomized control trial
Choroidal Thickness Measurements During Central Serous Chorioretinopathy (CSCR) Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine changes in choroidal thickness in patients with Central Serous Chorioretinopathy (CSCR) during the first 3 months after initial diagnosis via Enhanced-Depth-Imaging-Spectral-Domain-Optical-Coherence-Tomography (EDI-OCT). Study hypothesis: Since exudative changes in the choroid seem to constitute the primary pathology of CSCR, changes in choroidal thickness compared to healthy eyes should be present and be visible using EDI-OCT.

Official Title
-----------------
Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology

Conditions
-----------------
Choroidal Thickness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with initial diagnosis of CSCR and no treatment so far Exclusion Criteria: Therapy (drugs/laser) due to CSCR

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CSCR-Patients<br>Patients suffering from Central Serous Chorioretinopathy | |
| Healthy Subjects<br>Healthy subjects with (assumed) normal choroidal thickness | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Expanded Access to RXDX-105 for Cancers With RET Alterations

Study Overview
=================
Brief Summary
-----------------
Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Official Title
-----------------
Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations

Conditions
-----------------
Cancers With RET Alterations

Intervention / Treatment
-----------------
* Drug: RXDX-105


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of advanced cancer with RET alterations Unable to participate in an ongoing RXDX-105 clinical trial Willing and able to provide written, signed informed consent Medically suitable for treatment with RXDX-105 Exclusion Criteria: Prior treatment with a TKI that has activity against RET alterations Currently enrolled in an ongoing clinical study with any other investigational agent
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: RXDX-105|Oral Capsules|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis

Study Overview
=================
Brief Summary
-----------------
STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis Using Integration Of Fitness Technology and Port CF. A pilot in integration of wearable fitness tracker data with existing health data provided by CF foundation Patient Registry (Port CF)

Official Title
-----------------
STimulating ImProved Health And Well-being In CysTic Fibrosis Using Integration Of Fitness Technology and Port CF.

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Device: Fitbit Tracker


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with Cystic Fibrosis Age >18, Cystic Fibrosis Exclusion Criteria: A potential subject who meets any of the following exclusion criteria is ineligible to participate in the study. Those unable to commit to at least 3 months follow up for CF care from enrollment at study CF center. Inability to speak and understand English. Those patients without dedicated access to a smartphone, tablet, or computer with internet for syncing device and completing patient diary. Those patients unwilling to sign an informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Interventional - Fitbit tracker<br>Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness | Device: Fitbit Tracker<br>* Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants will Consistently Use Fitbit Tracker | Demonstrate that participants will consistently use and upload data from the fitness tracker as measured by use of at least 20 hours per day and uploading of at least 75% of activity. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Integration Tool Development | Develop integration tool for the data from the Fitbit with data from Cystic Fibrosis Foundation Patient Registry. | 1 year |
Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of SA4503 in patients recovering from a recent stroke. Secondary, to evaluate the efficacy of SA4503 compared to placebo.

Detailed Description
-----------------
Further study details as provided by M's Science Corporation:

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Phase IIa Study of Safety and Motor Function Restoration in Subjects Treated With SA4503 Following Acute Ischemic Stroke

Conditions
-----------------
Ischemic Stroke

Intervention / Treatment
-----------------
* Drug: placebo
* Drug: SA4503 Low
* Drug: SA4503 High


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Males or females 18 years of age or older Experienced a stroke from 48 to 72 hours before randomization A total score of >/=4 on the NIHSS, or >/=2 on the upper or lower extremity motor scores of the NIHSS Medically and neurologically stable within 24 hours prior to randomization Key Exclusion Criteria: Patients with transient ischemic attack Patients with stroke in progression Unstable cardiac, hepatic, or renal disease, or other major medical disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: P<br>Placebo | Drug: placebo<br>* Oral administration<br>|
| Experimental: A1<br>SA4503 | Drug: SA4503 Low<br>* Oral administration<br>|
| Experimental: A2<br>SA4503 | Drug: SA4503 High<br>* Oral administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NIHSS |  | 4 weeks |
TRIGGERING AND PROTECTIVE FACTORS OF BURNOUT IN MEDICAL RESIDENT

Study Overview
=================
Brief Summary
-----------------
Residents and interns are prone to emotional and physical exhaustion, also known as burnout. Burnout has not been studied much in physicians working in lower-middle income countries. We conducted this cross-sectional study at two institutes to determine the burden of burnout among internal medicine residents and to identify triggering and protective factors associated with burnout. An abbreviated version of the Maslach Burnout scale was used to measure burnout, and protective and triggering factors were recorded according to known factors.

Official Title
-----------------
TRIGGERING AND PROTECTIVE FACTORS OF BURNOUT IN MEDICAL RESIDENT PHYSICIANS IN A LOWER-MIDDLE-INCOME COUNTRY: A CROSS-SECTIONAL STUDY

Conditions
-----------------
Burnout, Professional

Intervention / Treatment
-----------------
* Other: No intervention. only observational cross sectional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All residents of the internal medicine program at both institutes Exclusion Criteria: Residents who were part of a flexible training program, working in shifts and those who had done less than six months of training were excluded
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention. only observational cross sectional study|No intervention done. only observational cross sectional study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Burnout | Burden of Burnout | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Triggering factors | Triggering factors for burnout | 1 year | 
| Protective factors | Protective factors for burnout | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Burnout, Residents, Medicine, Pakistan